在NSCLC中不可预见的N2疾病的真实患病率:系统审查+元分析
Wing Kea Hui1, Zohra Charaf2, Jeroen M H Hendriks1,3
1Department of Thoracic and Vascular Surgery, University Hospital Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Cancers
|July 14, 2023
概括
肺癌患者中未预见的N2 (uN2) 疾病的患病率为7.97%,尽管发生了分期. 完全切除可能提供与IIb阶段相似的预后,这需要进一步研究辅助疗法.
科学领域:
- 胸部瘤学 胸部瘤学
- 手术瘤学手术瘤学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 传统上,未预见的N2 (uN2) 疾病表明肺癌患者的预后不佳.
- 在手术前和手术后的中间体分期方面的进展影响了观察到的N2疾病的流行率.
研究的目的:
- 评估当前关于未预见的N2 (uN2) 疾病的证据.
- 为了确定N2疾病在肺癌中的患病率和预后影响.
主要方法:
- 针对NN2疾病的研究进行了系统的文献搜索,直到2023年4月6日.
- 纽卡斯尔-太华尺度 (NOS) 用于评估22项纳入研究的质量,包括9387名患者的流行率和892名患者的生存分析.
主要成果:
- 真正未预见的PN2疾病的综合患病率为7.97% (95%CI为6.67-9.27%),尽管有足够的中间体分期.
- 患有N2疾病的患者的整体5年生存率 (OS) 是44% (95% CI 31-58%).
- 研究之间的显著异质性限制了元分析.
结论:
- 患有N2疾病的患者,如果完成完整的手术切除,预后可能与IIb期肺癌相似.
- 在患有N2疾病的患者中,辅助治疗的作用和益处需要进一步研究.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
06:03Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
Published on: May 23, 2015
22.4K
相关概念视频
Cancer Survival Analysis
394
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
394
Prevalence and Incidence
634
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
634
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
